Total joint arthroplasty in patients with chronic infectious liver disease

The opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant technologies, and improvement of techniques in TJA. Unfortunately, treating this gr...

Full description

Bibliographic Details
Main Authors: Jeremy N. Truntzer, MD, Kalpit N. Shah, MD, Derek R. Jenkins, MD, Lee E. Rubin, MD
Format: Article
Language:English
Published: Elsevier 2016-06-01
Series:Arthroplasty Today
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352344115000515
id doaj-f81a83d44f4b4959877e174fbed4bd82
record_format Article
spelling doaj-f81a83d44f4b4959877e174fbed4bd822020-11-25T02:29:30ZengElsevierArthroplasty Today2352-34412016-06-0122697610.1016/j.artd.2015.07.001Total joint arthroplasty in patients with chronic infectious liver diseaseJeremy N. Truntzer, MD0Kalpit N. Shah, MD1Derek R. Jenkins, MD2Lee E. Rubin, MD3Department of Orthopaedics, Stanford University, Stanford CA, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAThe opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant technologies, and improvement of techniques in TJA. Unfortunately, treating this group of patients is not without significant challenges that can stem from both intrahepatic and extrahepatic clinical manifestations. Moreover, many subclinical changes occur in this cohort that can alter hemostasis, wound healing, and infection risk even in the asymptomatic patient. In this review, we discuss the various clinical presentations of chronic infectious liver disease and summarize the relevant literature involving total joint arthroplasty for this population. Hopefully, through appropriate patient selection and perioperative optimization, treating surgeons should see continued improvement in outcomes for patients with chronic infectious liver disease.http://www.sciencedirect.com/science/article/pii/S2352344115000515Total joint arthroplastyHepatitis CHepatitis BCirrhosis
collection DOAJ
language English
format Article
sources DOAJ
author Jeremy N. Truntzer, MD
Kalpit N. Shah, MD
Derek R. Jenkins, MD
Lee E. Rubin, MD
spellingShingle Jeremy N. Truntzer, MD
Kalpit N. Shah, MD
Derek R. Jenkins, MD
Lee E. Rubin, MD
Total joint arthroplasty in patients with chronic infectious liver disease
Arthroplasty Today
Total joint arthroplasty
Hepatitis C
Hepatitis B
Cirrhosis
author_facet Jeremy N. Truntzer, MD
Kalpit N. Shah, MD
Derek R. Jenkins, MD
Lee E. Rubin, MD
author_sort Jeremy N. Truntzer, MD
title Total joint arthroplasty in patients with chronic infectious liver disease
title_short Total joint arthroplasty in patients with chronic infectious liver disease
title_full Total joint arthroplasty in patients with chronic infectious liver disease
title_fullStr Total joint arthroplasty in patients with chronic infectious liver disease
title_full_unstemmed Total joint arthroplasty in patients with chronic infectious liver disease
title_sort total joint arthroplasty in patients with chronic infectious liver disease
publisher Elsevier
series Arthroplasty Today
issn 2352-3441
publishDate 2016-06-01
description The opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant technologies, and improvement of techniques in TJA. Unfortunately, treating this group of patients is not without significant challenges that can stem from both intrahepatic and extrahepatic clinical manifestations. Moreover, many subclinical changes occur in this cohort that can alter hemostasis, wound healing, and infection risk even in the asymptomatic patient. In this review, we discuss the various clinical presentations of chronic infectious liver disease and summarize the relevant literature involving total joint arthroplasty for this population. Hopefully, through appropriate patient selection and perioperative optimization, treating surgeons should see continued improvement in outcomes for patients with chronic infectious liver disease.
topic Total joint arthroplasty
Hepatitis C
Hepatitis B
Cirrhosis
url http://www.sciencedirect.com/science/article/pii/S2352344115000515
work_keys_str_mv AT jeremyntruntzermd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease
AT kalpitnshahmd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease
AT derekrjenkinsmd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease
AT leeerubinmd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease
_version_ 1724832708005199872